OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

13 Apr 2022

Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

OncoResponse's technology focuses on the tumor microenvironment and turning "cold" tumors "hot" • Source: Alamy

To hear OncoResponse Inc. CEO Clifford Stocks tell it, his company is “approaching that interesting time point where pharma likes to partner” as it readies lead candidate OR2805 for efficacy studies in solid tumors. Currently in Phase I, OR2805 is derived from B-cells harvested from an “elite responder” to a commercial anti-PD-1 therapy and may offer an approach for transforming “cold” tumors into immuno-responsive or “hot” ones.

With an antibody-discovering platform technology that Theraclone Sciences, Inc. once used in novel anti-infectious R&D, OncoResponse scientists can interrogate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

23 Jul 2025

• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.